Canton Strategic Holdings (CNTN) Cash from Financing Activities (2021 - 2026)
Canton Strategic Holdings (CNTN) reported Cash from Financing Activities of $87.0 million for Q1 2026, up 42200.79% on a YoY basis from N/an in Q1 2025, and down 10.76% quarter-over-quarter from $97.4 million in Q4 2025.
Canton Strategic Holdings (CNTN) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Cash from Financing Activities for 6 years, with the latest figure at $87.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 42200.79% year-over-year to $87.0 million; the trailing twelve-month figure through Mar 2026 stood at $193.9 million (up 5579.56% YoY), and the FY2025 full-year result was $107.2 million, up 2939.54% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $87.0 million, down from $97.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $97.4 million in Q4 2025, with the low at -$338585.0 in Q3 2022.
- Historically, Cash from Financing Activities has averaged $13.1 million across 5 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 485.1% — and 2026, when it surged 42200.79%.
- Canton Strategic Holdings' Cash from Financing Activities stood at -$193457.0 in 2022, then surged by 5094.25% to $9.7 million in 2023, then slumped by 81.18% to $1.8 million in 2024, then soared by 5257.28% to $97.4 million in 2025, then decreased by 10.76% to $87.0 million in 2026.
- The last three Cash from Financing Activities figures came in at $87.0 million (Q1 2026), $97.4 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 86.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.96 Mn |
| Mar 31, 2026 | 86.96 Mn |
| Dec 31, 2025 | 97.44 Mn |
| Dec 31, 2025 | 97.44 Mn |
| Sep 30, 2025 | 7.22 Mn |
| Sep 30, 2025 | 7.22 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | 205,568.00 |
| Mar 31, 2025 | 205,568.00 |
| Dec 31, 2024 | 1.82 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Sep 30, 2024 | -257,730.00 |
| Sep 30, 2024 | -257,730.00 |
| Jun 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 317,119.00 |
| Mar 31, 2024 | 317,119.00 |
| Dec 31, 2023 | 9.66 Mn |
| Dec 31, 2023 | 9.66 Mn |